000147408 001__ 147408
000147408 005__ 20240229123024.0
000147408 0247_ $$2doi$$a10.1016/j.jad.2019.10.025
000147408 0247_ $$2pmid$$apmid:31668601
000147408 0247_ $$2ISSN$$a0165-0327
000147408 0247_ $$2ISSN$$a1573-2517
000147408 037__ $$aDKFZ-2019-02525
000147408 041__ $$aeng
000147408 082__ $$a610
000147408 1001_ $$aBoehlen, Friederike H$$b0
000147408 245__ $$aGender-specific predictors of generalized anxiety disorder symptoms in older adults: Results of a large population-based study.
000147408 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2020
000147408 3367_ $$2DRIVER$$aarticle
000147408 3367_ $$2DataCite$$aOutput Types/Journal article
000147408 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1636705442_5417
000147408 3367_ $$2BibTeX$$aARTICLE
000147408 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147408 3367_ $$00$$2EndNote$$aJournal Article
000147408 500__ $$a2020 Feb 1;262:174-181.
000147408 520__ $$aAnxiety in older age is common. In comparison with men, older women experience higher levels of anxiety and show different patterns of co-occurring mental disorders. The aim of this study is to investigate gender-specific biopsychosocial predictors associated with GAD (Generalized Anxiety Disorder) symptoms after a period of three years in the elderly population.Data were derived from the third (2008-2010) and the fourth follow-up (2011-2014) of the large population-based German ESTHER study. 2254 participants ages 55-85 were included in the study (52.3% female; 47.7% male). Generalized Anxiety Disorder Symptoms were measured using the GAD-7 questionnaire at both follow-ups. Linear regression analyses were performed to predict GAD severity after three years; the analyses were separated by gender and adjusted for demographic variables, biopsychosocial health, cognitive impairment, loneliness, and psychosocial resources.In women, GAD severity after three years (t1) was positively associated with younger age, depression symptoms, loneliness, and GAD severity at t0. In men, GAD severity was positively associated with somatic symptoms as well as with GAD severity at t0. In both genders GAD severity at baseline was the strongest predictor of elevated future anxiety symptoms.GAD was examined by the use of questionnaires rather than by personal assessment; underreporting of GAD symptoms is therefore possible.Our study shows that an increase as well as a decrease of GAD severity in older women and men can be predicted by several biopsychosocial variables.
000147408 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000147408 588__ $$aDataset connected to CrossRef, PubMed,
000147408 7001_ $$aHerzog, Wolfgang$$b1
000147408 7001_ $$aSchellberg, Dieter$$b2
000147408 7001_ $$aMaatouk, Imad$$b3
000147408 7001_ $$0P:(DE-HGF)0$$aSchoettker, Ben$$b4
000147408 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$udkfz
000147408 7001_ $$aWild, Beate$$b6
000147408 773__ $$0PERI:(DE-600)1500487-9$$a10.1016/j.jad.2019.10.025$$gp. S0165032718329082$$p174-181$$tJournal of affective disorders$$v262$$x0165-0327$$y2020
000147408 909CO $$ooai:inrepo02.dkfz.de:147408$$pVDB
000147408 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000147408 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000147408 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000147408 9141_ $$y2020
000147408 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000147408 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000147408 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000147408 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ AFFECT DISORDERS : 2017
000147408 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000147408 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000147408 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000147408 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000147408 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000147408 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000147408 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000147408 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index
000147408 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences
000147408 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000147408 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000147408 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000147408 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000147408 980__ $$ajournal
000147408 980__ $$aVDB
000147408 980__ $$aI:(DE-He78)C070-20160331
000147408 980__ $$aUNRESTRICTED